OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive Questions and Answers document in advance of its Annual General Meeting (AGM) convened on September 30, 2025. The document provides clear, factual information about financing, governance, scientific development and the Company’s strategy. O

26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2] Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and

Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The agreement between Santhera and Ikris has a 5-year term and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to

The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program. “It is a ‘solution’ in search of a problem,” the AHA wrote to HRSA. “More accurately, it is a ‘solution’ that will create a host of problems for those who provide care for rural and other underserved Americans. But given the agency’s apparent interest in forging ahead, HRSA must impose stronger, inescapable safeguards — including a method to ensure that drug companies pay for

The AHA Aug. 28 published a blog responding to a series of reports from the Paragon Health Institute alleging large-scale “fraud” in health care, this time focusing on enrollment in the Health Insurance Marketplace. The blog discusses how Paragon uses these allegations as rationale for a set of policy recommendations, including allowing the enhanced premium tax credits to expire at the end of 2025. “If adopted by Congress, this policy would result in millions of Americans losing health care cove

The AHA Aug. 28 expressed support for the Preserving Patient Access to Accountable Care Act in comments to House and Senate sponsors of the bill. The legislation would extend Medicare’s Advanced Alternative Payment Model incentive payments and maintain adequate qualifying thresholds. “The Medicare Advanced APM incentive payments prevent attrition in value-based care models and provide crucial resources to hospitals and health systems,” the AHA wrote. “Although clinicians who participate in Advan

BeOne Medicines said it will seek regulatory approvals in the US and elsewhere globally for sonrotoclax (BGB-11417), following the release of positive topline data from a Phase I/II trial in relapsed or refractory mantle cell lymphoma (MCL). The 125-patient study met its primary endpoint of overall response rate, positioning the next-generation BCL2 inhibitor for potential approval in the rare and aggressive form of blood cancer.The trial enrolled adult patients whose disease had progressed foll

Zydus Therapeutics is planning to file for FDA approval of its liver disease candidate early next year after saroglitazar met the primary endpoint of the EPICS-III Phase IIb/III trial in patients with primary biliary cholangitis (PBC) — setting it up to compete with Gilead Sciences and Ipsen. Zydus is the US-based speciality arm of Indian pharma Zydus Lifesciences. Similar to Gilead's Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor), saroglitazar is a PPAR agonist, but while the former is

Partners Biogen and Eisai have scored a key approval in their mission to improve the accessibility of Alzheimer's disease drug Leqembi (lecanemab). The FDA on Friday approved a subcutaneous (SC) formulation of the anti–beta-amyloid antibody, dubbed Leqembi IQLIK, for maintenance dosing. Currently, the drug is given as an hour-long infusion every two weeks, but now, after 18 months of treatment, patients can switch to a weekly at-home injection. Friday's green light marks the second for Leqembi t

Johnson & Johnson on Thursday said it has halted clinical development of its FcRn blocker Imaavy (nipocalimab) in combination with UCB’s anti-TNFα therapy Cimzia (certolizumab pegol) for rheumatoid arthritis after a mid-stage proof-of-concept study showed underwhelming results.The Phase IIa DAISY study enrolled 103 adult patients with moderate to severe active rheumatoid arthritis for ≥3 months who were refractory to biologic disease-modifying anti-rheumatic drugs or anti-TNF agents. The partici